long-acting PTH — IND submission
late 2026
We intend to accelerate development and currently expect to submit an IND application to the FDA in late 2026.Source filing
ENTX biotech catalysts & pipeline
ENTERA BIO LTD · Data as of 2026-10-25
Upcoming catalysts
EB612 — IND submission
H1 2027
Following the previously announced expansion of the Company's collaboration with OPKO Health ("OPKO") in February 2026, Entera and OPKO intend to file an Investigational New Drug (IND) application for EB612 in the first half of 2027.Source filing
EB613 — Topline data
H2 2028
Entera plans to initiate the registrational Phase 3 study in late 2026, with topline results anticipated in the second half of 2028.Source filing